| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.2217/RME.15.12 |
| P698 | PubMed publication ID | 25933241 |
| P50 | author | Alain Vertès | Q67880090 |
| P2093 | author name string | Alain A Vertès | |
| P2860 | cites work | Hematopoietic stem cell transplantation: a global perspective | Q24624697 |
| Separation of graft-vs.-tumor effects from graft-vs.-host disease in allogeneic hematopoietic cell transplantation | Q24642254 | ||
| Progress and prospects for engineered T cell therapies | Q26852923 | ||
| Current and emerging strategies for the prevention of graft-versus-host disease | Q27016541 | ||
| Cord blood stem cells for hematopoietic stem cell transplantation in the UK: how big should the bank be? | Q33451570 | ||
| Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data | Q33543723 | ||
| Bone marrow mesenchymal stromal cells to treat complications following allogeneic stem cell transplantation | Q33648765 | ||
| Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells | Q33858964 | ||
| Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy | Q33969561 | ||
| Current status of umbilical cord blood hematopoietic stem cell transplantation | Q34076814 | ||
| Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. | Q34077792 | ||
| A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. | Q34144404 | ||
| Mesenchymal stem cell therapy and acute graft-versus-host disease: a review | Q34294935 | ||
| Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis | Q34337007 | ||
| Umbilical cord blood transplantation: the first 25 years and beyond | Q34344669 | ||
| Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation | Q34517135 | ||
| Treatment costs and survival in patients with grades III-IV acute graft-versus-host disease after allogenic hematopoietic stem cell transplantation during three decades | Q34537493 | ||
| Effector CD4+ T cells, the cytokines they generate, and GVHD: something old and something new. | Q34754302 | ||
| Graft-versus-leukemia effects of transplantation and donor lymphocytes | Q34887477 | ||
| Attributable hospital cost and antifungal treatment of invasive fungal diseases in high-risk hematology patients: an economic modeling approach | Q34932560 | ||
| Many mechanisms mediating mobilization: an alliterative review | Q35173866 | ||
| Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria | Q35483810 | ||
| Steroid-Refractory Acute GVHD: Predictors and Outcomes. | Q35550596 | ||
| Antigen CD34+ marrow cells engraft lethally irradiated baboons | Q35587124 | ||
| Plasma biomarkers of lower gastrointestinal and liver acute GVHD. | Q35891657 | ||
| Antilymphocyte/thymocyte globulin for graft versus host disease prophylaxis: efficacy and side effects | Q35959473 | ||
| Shared biology of GVHD and GVT effects: potential methods of separation | Q36278206 | ||
| Pathophysiology of graft-versus-host disease | Q36368101 | ||
| Hematopoietic stem-cell transplantation | Q36461248 | ||
| Novel strategies for the treatment and diagnosis of graft-versus-host-disease | Q36750653 | ||
| Hematopoietic cell transplantation: progress and obstacles | Q36758830 | ||
| Graft-versus-host disease | Q36793622 | ||
| Dissecting graft-versus-leukemia from graft-versus-host-disease using novel strategies | Q36819337 | ||
| What predicts high risk acute graft-versus-host disease (GVHD) at onset?: identification of those at highest risk by a novel acute GVHD risk score | Q36846650 | ||
| Concise review: acute graft-versus-host disease: immunobiology, prevention, and treatment | Q36861714 | ||
| Acute graft-versus-host disease in children | Q36970235 | ||
| HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide | Q37078261 | ||
| Current and novel therapies in acute GVHD. | Q37173464 | ||
| Acute GvHD: pathogenesis and classification | Q37188484 | ||
| Prevention and treatment of acute GvHD. | Q37188487 | ||
| Advances in the treatment of acute graft-versus-host disease. | Q37191057 | ||
| Novel drugs for the prevention and treatment of acute GVHD. | Q37239863 | ||
| Prophylaxis regimens for GVHD: systematic review and meta-analysis | Q37322076 | ||
| Optimizing unrelated donor cord blood transplantation | Q37369445 | ||
| Genetically engineered donor T cells to optimize graft-versus-tumor effects across MHC barriers | Q37416883 | ||
| History of cord blood transplantation | Q37607988 | ||
| Optimal management of chronic graft-versus-host disease in children | Q37765607 | ||
| Mesenchymal Stem Cells: Mechanisms of Inflammation | Q37809081 | ||
| New strategies for haploidentical transplantation | Q37978777 | ||
| Emerging concepts in haematopoietic cell transplantation | Q38013047 | ||
| Anti-thymocyte globulins for post-transplant graft-versus-host disease prophylaxis-A systematic review and meta-analysis | Q38096525 | ||
| Cord Blood Transplantation: Can We Make it Better? | Q38142167 | ||
| Mesenchymal stromal cells: sensors and switchers of inflammation | Q38149359 | ||
| Hematopoietic stem cell transplantation activity in Europe. | Q38150626 | ||
| One million haemopoietic stem-cell transplants: a retrospective observational study | Q38384271 | ||
| The potential of cytotherapeutics in hematologic reconstitution and in the treatment and prophylaxis of graft-versus-host disease. Chapter II: emerging transformational cytotherapies. | Q39012031 | ||
| History of hematopoietic stem cell transplantation: evolution and perspectives | Q39646495 | ||
| Graft-versus-host disease in dog and man: the Seattle experience | Q39839309 | ||
| Cord blood CD4(+)CD25(+)-derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function | Q40514795 | ||
| The best endpoint for acute GVHD treatment trials | Q43100931 | ||
| Duration of immunosuppressive treatment for chronic graft-versus-host disease | Q43590716 | ||
| Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide | Q44097089 | ||
| Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems | Q44097093 | ||
| Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia | Q44499780 | ||
| Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. | Q45745053 | ||
| Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome | Q47359749 | ||
| Assessment of optimal size and composition of the U.S. National Registry of hematopoietic stem cell donors. | Q47413726 | ||
| Graft-versus-leukemia effects in T lineage and B lineage acute lymphoblastic leukemia | Q47626366 | ||
| Hematopoietic-cell transplantation at 50. | Q48546980 | ||
| Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer | Q48881552 | ||
| Extracorporeal photopheresis versus anticytokine therapy as a second-line treatment for steroid-refractory acute GVHD: a multicenter comparative analysis. | Q51036325 | ||
| Economics of hematopoietic cell transplantation. | Q51588444 | ||
| Plerixafor on-demand combined with chemotherapy and granulocyte colony-stimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs. | Q51776428 | ||
| History of haematopoietic stem-cell transplantation. | Q53437646 | ||
| Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius | Q56525543 | ||
| Hematopoietic SCT activity in Asia: a report from the Asia-Pacific Blood and Marrow Transplantation Group | Q56752696 | ||
| Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy | Q56777948 | ||
| Steroid-Refractory Acute GVHD: Lack of Long-Term Improved Survival Using New Generation Anticytokine Treatment | Q58814216 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 331-343 | |
| P577 | publication date | 2015-01-01 | |
| P1433 | published in | Regenerative Medicine | Q19921466 |
| P1476 | title | The potential of cytotherapeutics in hematologic reconstitution and in the treatment and prophylaxis of graft-versus-host disease. Chapter I: current practice and remaining unmet medical needs | |
| P478 | volume | 10 |
| Q47246973 | Methods and practices to diversify cell-based products |
| Q48039450 | Taming the lion: the challenge of immunity in regenerative medicine |
| Q39012031 | The potential of cytotherapeutics in hematologic reconstitution and in the treatment and prophylaxis of graft-versus-host disease. Chapter II: emerging transformational cytotherapies. |
Search more.